@article{8d14e2ebdf3b4dfe96ba88879caab81d,
title = "Randomized, {\textquotedblleft}head-to-head{\textquotedblright} studies comparing different SGLT2 inhibitors are definitely needed",
author = "Kazuomi Kario and Noriko Harada and Satoshi Hoshide",
note = "Funding Information: Prof. K Kario has received research grants from Astellas Pharma Inc, Eisai Co., Otsuka Pharmaceutical Co., Sanofi KK, Shionogi \& Co., Sanwa Kagaku Kenkyusho Co., Daiichi Sankyo Co., Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Boehringer Ingelheim Japan Inc, Pfizer Japan Inc, Bristol‐Myers Squibb KK, and Mochida Pharmaceutical Co. and lecture fees from Idorsia Pharmaceuticals Japan, Daiichi Sankyo Co., and Takeda Pharmaceutical Co. All other authors have no conflicts of interest to disclose.",
year = "2020",
month = dec,
doi = "10.1111/jch.14077",
language = "English",
volume = "22",
pages = "2391--2392",
journal = "Journal of Clinical Hypertension",
issn = "1524-6175",
publisher = "John Wiley and Sons Inc.",
number = "12",
}